Biovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH Meeting

  Biovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition
  Patient Advocacy Event prior to ASH Meeting

Business Wire

TAMPA, Fla. & MINNEAPOLIS -- December 04, 2012

Biovest International, Inc. (OTCQB: “BVTI”), a majority-owned subsidiary of
Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”), today announced that
Biovest will present at the Lymphoma Coalition’s annual patient advocacy event
leading up to the American Society of Hematology (ASH) Annual Meeting in
Atlanta, Dec. 8-11. Biovest will provide an update on BiovaxID™, its
late-stage, personalized cancer vaccine for the treatment of non-Hodgkin’s
lymphoma, which has been featured in a series of recent web-based articles by
lymphoma patient advocates reporting on the urgent, unmet need for additional
consolidation therapeutic options for lymphoma patients concerned with safety
and side-effects.

BiovaxID Presentation Details:

Event: Lymphoma Coalition Presentation & Reception Evening

Day/Time: Thursday, December 6^th at 4:30 pm EST

Place: Marriott Perimeter Centre, 246 Perimeter Centre Parkway NE, Atlanta,
Georgia

For More Information: www.lymphomacoalition.org

To review articles by lymphoma patient advocates reporting on BiovaxID and the
unmet need for additional consolidation therapeutic options, please visit the
following publication links:

  *AnnArbor.Com
    http://www.annarbor.com/health/patients-fight-back-when-the-fda-refuses-to-review-a-new-cancer-therapy/
  *LymphomaInfo.Net
    http://www.lymphomainfo.net/lifestyle/non-hodgkins/follicular/sign-the-petition-to-bring-the-lymphoma-vaccine-to-market

To request a meeting with Biovest at this Lymphoma Coalition event or at ASH,
please contact Douglas Calder at 813-507-2558 or dwcalder@biovest.com.

About Biovest International, Inc.

Biovest International, Inc. develops active immunotherapies (cancer vaccines)
which treat and diminish the aggressiveness of B-cell non-Hodgkin’s lymphoma,
a cancer of the immune system. The Company’s lead personalized cancer vaccine
product candidate, BiovaxID™, has been evaluated in three clinical trials
conducted in collaboration with the U.S. National Cancer Institute (NCI)
demonstrating that BiovaxID increases the duration of cancer remission
following chemotherapy and induces immune responses which correlate highly
with long-term survival. Biovest is currently in the process of pursuing
European and Canadian marketing approvals for BiovaxID.

Headquartered in Tampa, Florida with its bio-manufacturing facility based in
Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQB™ Market with
the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia
Biopharmaceuticals, Inc. (OTCQB: “ABPI”).

        For further information, please visit: http://www.biovest.com

Forward-Looking Statements:

Statements in this press release that are not strictly historical in nature
constitute "forward-looking statements.” Such statements include, but are not
limited to, statements about Biovest and its product candidate, BiovaxID™ and
any other statements relating to products, product candidates, product
development programs, the FDA, the EMA, Health Canada or clinical study
process including the commencement, process, or completion of clinical trials
or the regulatory process. Such statements may include, without limitation,
statements with respect to the Company's plans, objectives, expectations and
intentions, and other statements identified by words such as "may," "could,"
"would," "should," "believes," "expects," "anticipates," "estimates,"
"intends," "plans," or similar expressions. In particular (and without
limitation), statements regarding the timing of anticipated filing of a
Marketing Authorization Application for BiovaxID with the EMA or a New Drug
Submission for BiovaxID with Health Canada, pre-filing meetings with the FDA
or other jurisdictions and/or commercial plans reflect current expectations
but are subject to inherent risks of delay in compilation and finalization of
all components of the licensing application. Such forward-looking statements
involve known and unknown risks, uncertainties, and other factors that may
cause the actual results of Biovest to be materially different from historical
results or from any results expressed or implied by such forward-looking
statements. These factors include, but are not limited to, risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for product candidates; competition from other
pharmaceutical or biotechnology companies; and the additional risks discussed
in filings with the Securities and Exchange Commission. All forward-looking
statements are qualified in their entirety by this cautionary statement, and
Biovest undertakes no obligation to revise or update this news release to
reflect events or circumstances after the date hereof. The product names used
in this statement are for identification purposes only. All trademarks and
registered trademarks are the property of their respective owners.

Contact:

Biovest International, Inc.
Douglas Calder, 813-864-2558
Vice President, Strategic Planning & Capital Markets
Email: dwcalder@biovest.com
 
Press spacebar to pause and continue. Press esc to stop.